MorrowDAPaolassoEOphuisAJO, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med2012; 366: 1404–1413.
2.
QamarAOlinJWBeckmanJA, et al. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial. Vasc Med2020; 25: 124–132.
3.
GornikHLAronowHDGoodneyPP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation2024; 149: e1313–e1410.
4.
Uslu-BiçakİNalçaciMSözerS. Targeting PAR1 activation in JAK2V617F-driven philadelphia-negative myeloproliferative neoplasms: Unraveling its role in thrombosis and disease progression. Neoplasia2025; 63: 101153.
5.
TsaiSAlaitiMABanerjeeS, et al. No benefit of vorapaxar on walking performance in patients with intermittent claudication. Vasc Med2021; 27: 33–38.
6.
FreedmanBLBergDDSciricaBM, et al. Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P-TIMI 50 trial. Clin Cardiol2022; 45: 831–838.
